FDA clears Interpore's spinal implant:
This article was originally published in Clinica
Interpore Cross International has received US FDA 510(k) clearance to market its implantable device for restoring biomechanical integrity of the spine following surgery for fractures or tumours in the spine. The telescopic plate spacer thoracolumbar spinal system implant is expected to be launched in the first quarter of 2002. The Irvine, California firm says that around 16,000 procedures are performed each year to remove tumours in the thoracolumbar spine, suggesting a total potential annual market of more than $60 million.
You may also be interested in...
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.